ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Targeted inhibition of miR-503 upregulates Apelin expression to alleviate myocardial infarction in mice].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo investigate the effect of inhibiting miR-503 on myocardial infarction (MI) and clarify its upstream regulatory factors and downstream effector pathways to identify potential therapeutic targets for MI.
methodsMouse models of MI established by ligation of the left anterior descending coronary artery were treated with intravenous injections of normal saline, antagomir-503 or antagomiR-NC (
resultsMiR-503 expression was significantly upregulated in both MI mouse hearts and hypoxic cardiomyocytes. In MI mouse models, antagomir-503 significantly improved cardiac function, reduced infarct size, downregulated Bax and cleaved caspase-3 expressions, and upregulated Apelin expression. In hypoxic neonatal rat cardiomyocytes, treatment with AMO-503 significantly enhanced cell viability, decreased cell apoptosis rate, and restored mitochondrial membrane potential. Mechanistically, the long non-coding RNA AK134630 could bind to and negatively regulate miR-503, and inhibition of miR-503 effectively relieved the inhibitory effect of RNA AK134630 on the downstream target gene Apelin.
conclusionsInhibition of miR-503 alleviates MI injury in mice by upregulating Apelin expression to inhibit cardiomyocyte apoptosis and protect mitochondrial function, and AK134630 participates in this regulatory mechanism as an upstream ceRNA of miR-503.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.